Skin involvement and outcome measures in systemic autoimmune diseases

Clinical and Experimental Rheumatology

Volumn 24, Issue SUPPL. 40, 2006, Pages

  Albrecht, J ^a   Atzeni, F ^b   Baldini, C ^c   Bombardieri, S ^c   Dalakas, M C ^d   Demirkesen, C ^e   Yazici, H ^e   Mat, C ^e   Werth, V P ^a   Sarzi Puttini, Piercarlo ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Beh et's syndrome; Cutaneous lupus erythematosus; Dermatomyositis; Primary Sj gren's syndrome; Rheumatoid arthritis; Rheumatoid nodules

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; HYDROXYCHLOROQUINE SULFATE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE ACETATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PROBENECID; PYRAZOLONE DERIVATIVE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; URATE;

ANGIONEUROTIC EDEMA; APHTHOUS STOMATITIS; APPLICATION SITE INFLAMMATION; AUTOIMMUNE DISEASE; BEHCET DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ELECTROMYOGRAPHY; ERYTHEMA; EYELID EDEMA; FOLLICULITIS; GRANULOMA ANNULARE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; LEG ULCER; LEUKOCYTOCLASTIC VASCULITIS; LICHENOID ERUPTION; MUSCLE BIOPSY; NONHUMAN; OUTCOME ASSESSMENT; PANNICULITIS; PATHOPHYSIOLOGY; PIGMENT DISORDER; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PURPURA; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SJOEGREN SYNDROME; SKIN DISCOLORATION; SKIN MANIFESTATION; SKIN NODULE; THROMBOPHLEBITIS; URTICARIA; VASCULITIS; XERODERMA; XEROSIS;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BEHCET SYNDROME; DERMATOMYOSITIS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RHEUMATOID NODULE; SJOGREN'S SYNDROME; SKIN DISEASES;

EID: 33645037689     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. HARRIS ED JR: Rheumatoid arthritis. Curr Opin Rheumatol 1994; 6: 287-9.
2. CHEN KR, TOYOHARA A, SUZUKI A et al.: Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 2002; 147: 905-13.
3. MAGRO CM, CROWSON AN: The spectrum of cutaneous lesions in rheumatoid arthritis: a clinical and pathological study of 43 patients. J Cutan Pathol 2003. 30: 1-10.
4. ZIFF M: The rheumatoid nodule. Arthritis Rheum 1990; 33: 761-7.
5. CHU P, CONNOLLY MK, LEBOIT PE: The histopathologic spectrum of palisaded neutrophilic granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol 1994; 130: 1278-83.
6. CROWSON AN, MIHM MC Jr, MAGRO CM: Cutaneous vasculitis: a review. J Cutan Pathol 2003; 30:161-73.
7. JORIZZO JL, DANIELS JD: Dermatological conditions reported in patients with rheumatoid arthritis. J Am Acad Dermatol 1983; 8: 439-57.
8. WALLACH D: Neutrophilic dermatoses. Rev Med Interne 2005; 26: 41-53.
9. AL-KHENAIZAN S, SCHECHTER IF, SASSEVILLE D: Pseudoporphyria induced by propionic acid derivatives. J Cutan Med Surg 1999; 3: 162-6.
10. SMITH RW, LEPPARD B, BARNETT NL et al.: Chrysiasis revisited: a clinical and pathological study. Br J Dermatol 1995; 133: 671-8.
11. DEVOS SA, Van Den BOSSCHE N, DE VOS M et al.: Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206: 388-90.
12. BENDELE A, McABEE T, SENNELLO G et al.: Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42: 498-506.
13. RAMOS CASALS M, TZIOUFAS AG, FONT J: Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64: 347-54.
14. ROGUEDAS AM, MISERY L, SASSOLAS B, LE MASSON G, PENNEC YL, YOUINOU P: Cutaneous manifestations of primary Sjögren's syndrome are underestimated. Clin Exp Rheumatol 2004; 22: 632-6.
15. BLOCH KJ, BUCHANAN WW, WHOHL MJ: Sjögren's syndrome: a clinical, pathological and serological study of 62 cases. Medicine 1965; 44: 187-231.
16. WHALEY K, WILLIAMSON J, CHISOLM DM: Sjögren's syndrome sicca components. Q J Med 1973; 166: 279-302.
17. BERNACCHI E, AMATO L, PARODI A et al.: Sjögren's sindrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol 2004; 22: 55-62.
18. BELENGUER R, RAMOS-CASALS M, BRITOZERON P et al.: Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2005; 23: 351-6.
19. PROVOST TT, WATSON R: Cutaneous manifestations of Sjögren's syndrome. Dis Clin N Am 1992; 18: 609-16.
20. GONZALEZ-GAY MA, GARCIA-PORRUA C, SALVARANI C, SCOCCO G, PUJOL RM: Cutaneous vasculitis: a diagnostic approach. Clin Exp Rheumatol 2003; 21: S85-S88.
21. VOULGARELIS M, DAFNI UG, ISENBERG DA, MOUTSOPOULOS HM: Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjögren's syndrome. Arthritis Rheum 1999; 42: 1765-72.
22. SELVA O' CALLAGHAN A, PEREZ-LOPEZ J, SOLANS-LAQUE R et al.: Primary cutaneous large B-cell lymphoma of the legs in a patient with primary Sjögren's syndrome. Clin Exp Rheumatol 2003; 21: 672.
23. DALAKAS MC: Inflammatory myopathies and toxic myopathies. Curr Opin Neurol Neurosurg 1992; 5: 645-54.
24. DALAKAS MC: Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991; 325: 1487-98.
25. DALAKAS MC: Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol 2003; 23: 199-206.
26. DALAKAS MC: Polymyositis, dermatomyositis and inclusion body myositis. In: BRAUNWALD E, FAUCI AS, KASPER DL, HAUSER SL, LONGO DL, JAMESON JL (Eds.): Harrison's Principles of Internal Medicine. 15th ed. McGraw-Hill, New York, 2001;2524.
27. DALAKAS MC, KARPATI G: The inflammatory myopathies. In: KARPATI G, HILTON-JONES, GRIGGS RC (Eds.): Disorders of Voluntary Muscle. 7th ed. Cambridge University Press 2001; 636.
28. DALAKAS MC, HOHLFELD R: Polymyositis and dermatomyositis. Lancet 2003; 362:971-82.
29. SONTHEIMER RD: Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin 2002; 20: 387-408.
30. GHERARDI RK, COQUET M, CHERIN P et al.: Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM). Lancet 1998; 352: 347-52.
31. CALLEN JP: Dermatomyositis. Lancet 2000; 355: 1186.
32. DALAKAS MC: Current treatment of the inflammatory myopathies. Curr Opin Rheumatol 1994; 6: 595-601.
33. HAREL L, HAREL G, KORENREICH L, STRAUSSBERG R, AMIR J: Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rheumatol 2001; 28: 1129-32.
34. MUKAMEL M, HOREY G, MIMOUNI M: New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 2001; 138: 763-6.
35. COSGUN S, SEYAHI E, MAT C, YAZICI H: Female Behçet's syndrome patients have more severe oral ulceration. Clin Exp Rheumatol 2004; 22: S 86.
36. MAT C, GOKSUGUR N, ERGIN B, YURDAKUL S, YAZICI H: The frequency of scarring after genital ulcers in Behçet's syndrome: a prospective study. Int J Dermatol 2005 in press.
37. TUNÇ R, KEYMAN E, MELIKOǦLU M, FRESKO I, YAZICI H: Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. J Rheumatol 2002; 29: 2393-6.
38. DIRI E, MAT C, HAMURYUDAN V, YURDAKUL S, HIZLI N, YAZICI H: Papulopustular skin lesions are seen more frequently in patients with Behçet's syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 200 1; 60: 1074-6.
39. HATEMI G, BAHAR H, UVSAL S et al.: The pustular skin lesions in Behçet's syndrome are not sterile. Ann Rheum Dis 2004; 63: 1450-2.
40. YURDAKUL S, HEKIM N, SOYSAL T et al.: Fibrinolytic activity and d-dimer levels in Behçet's syndrome. Clin Exp Rheumatol 2005, in press.
41. KURAL-SEYAHI E, FRESKO I, SEYAHI N et al.: The long-term mortality and morbidity of Behçet syndrome. A 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 2003; 82: 60-7. 8.
42. TASLI ML, MAT C, DE SIMONE C, YAZICI H: Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Clin Exp Rheumatol 2004; 22: S 119.
43. MELIKOGLU M., FRESKO I, MAT C et al.: short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.
44. MAT C, YURDAKUL S, OZYAZGAN Y, UYSAL S, UYSAL O, YAZJCI H: A double blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2005, in press.
45. WILLIAMS HC: Is a simple generic index of dermatologic disease severity an attainable goal? Arch Dermatol 1997; 133: 1451-2.
46. FINLAY AY: Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 1996; 135: 509-15.
47. ANONYMOUS: Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31.
48. BERTH-JONES J, THOMPSON J, GRAHAM-BROWN RA: Evening primrose oil and atopic eczema. Lancet 1995; 345: 520.
49. CARROL CL, LANG W, SNIVELY B, FELDMAN SR, CALLEN J, JORIZZO, JL: Development and validation of the Dermatomyositis Skin Severity Index (DSSI). in press
50. VLACHOYIANNOPOULOS PG, KARASSA FB, KARAKOSTAS KX, DROSOS AA, MOUTSOPOULOS HM: Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 1993; 2: 303-12.
51. CHARMAN C, WILLIAMS H: Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000; 136: 763-9.
52. CHARMAN CR, VENN AJ, WILLIAMS HC: Measurement of body surface area involvement in atopic eczema: an impossible task? Br J Dermatol 1999; 140: 109-11.
53. TILING-GROSSE S, REES J: Assessment of area of involvement in skin disease: a study using schematic figure outlines. Br J Dermatol 1993; 128: 69-74.
54. ALBRECHT J, TAYLOR L, BERLIN J, DULAY S et al.: The CLASI (Cutaneous LE Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-94.